Home > Insider Trading > Filing (0001209191-14-065581)

Filing Details

Accession Number:: 0001209191-14-065581
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-10-31 16:50:27
Reporting Period:: 2014-10-29

Filing Date:: 2014-10-31
Accepted Time:: 2014-10-31 16:50:27
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1505512	Regulus Therapeutics Inc.	RGLS	Pharmaceutical Preparations (2834)	264738379

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1555918	W Neil Gibson	C/O Regulus Therapeutics Inc., 3545 John Hopkins Court, Suite 210 San Diego CA 92121	Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-10-29	2,500	$1.74	82,500	No	4	M	Direct
Common Stock	Disposition	2014-10-29	1,100	$18.68	81,400	No	4	S	Direct
Common Stock	Disposition	2014-10-29	1,200	$19.67	80,200	No	4	S	Direct
Common Stock	Disposition	2014-10-29	200	$20.41	80,000	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2014-10-29	2,500	$0.00	2,500	$1.74

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
114,000		2021-04-17	No	4	M	Direct

Footnotes

Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted August 26, 2013.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.30 to $19.27 inclusive. The reporting person undertakes to provide to RGLS, any security holder of RGLS, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.35 to $20.15 inclusive. The reporting person undertakes to provide to RGLS, any security holder of RGLS, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.40 to $20.41 inclusive. The reporting person undertakes to provide to RGLS, any security holder of RGLS, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
25% of the shares vested on April 18, 2012 and the remainder of the shares vest in equal installments on a monthly basis thereafter, such that the option is fully vested on April 18, 2015.